America’s biopharmaceutical companies’ have acted quickly to focus their expertise on treatments for COVID-19. Currently, treatments being tested range from antiviral and antibody therapies to anticoagulant and antimicrobial therapies – to target both the virus itself and the most dangerous health consequences of COVID-19.
Please join PhRMA member company executives for a townhall on COVID-19 therapeutic development – a unique forum to hear directly from leaders in the fight to beat COVID-19, including:
Ramona Sequeira, President, Takeda
David Ricks, Chairman and Chief Executive Officer, Eli Lilly and Company
Alexander Hardy, Chief Executive Officer, Genentech
Johanna Mercier, Chief Commercial Officer, Gilead